Neurona Therapeutics Secures $102M to Advance Breakthrough Cell Therapy for Epilepsy”

Funding Achievement:
Neurona Therapeutics has raised $102 million in an oversubscribed funding round, with contributions from major investors including Fidelity, Soleus Capital, and Viking Global Investors, to advance its innovative cell therapy pipeline5.

NRTX-1001 Therapy:
This investigational therapy, derived from human pluripotent stem cells, introduces GABAergic interneurons to the brain, aiming to restore neural balance and significantly reduce seizures in patients with drug-resistant mesial temporal lobe epilepsy (MTLE)1 5.

Promising Efficacy:
Early trials of NRTX-1001 showed dramatic seizure reductions. Notably, two Phase 1/2 trial participants reported over 95% seizure reduction for over a year post-treatment, with no serious adverse events or cognitive deficits observed1 3 5.

Planned Phase 3 Trials:
The $102 million will fund the EPIC trial, a pivotal Phase 3 study for NRTX-1001. This randomized, double-blind trial will assess the therapy’s efficacy and safety in drug-resistant MTLE patients5.

Regulatory Milestones:
NRTX-1001 received FDA approval under the Regenerative Medicine Advanced Therapy (RMAT) designation in 2024, highlighting its potential as a groundbreaking treatment option for epilepsy5 3.

Global Impact:
Epilepsy affects 50 million people globally, with up to one-third resistant to existing therapies. NRTX-1001 offers hope as a minimally invasive and durable alternative to brain surgery1 6 9.

Additional Applications:
Beyond epilepsy, Neurona is exploring NRTX-1001’s potential in other neurological conditions, such as Alzheimer’s disease, further expanding its therapeutic pipeline6 8.